Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1TNJ2
|
|||
| Drug Name |
XL092
|
|||
| Synonyms |
SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Exelixis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H25FN4O5
|
|||
| Canonical SMILES |
CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
|
|||
| InChI |
1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37)
|
|||
| InChIKey |
JSPCKALGNNVYOO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03845166) A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Exelixis. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.